Abstract:Microglial activation is intimately associated with Alzheimer's disease (AD), however its exact role in AD is unknown. Positron emission tomography (PET) imaging of translocator protein 18 kDa (TSPO), a biomarker of microglial activation, could enhance our understanding of the in vivo role of microglia in AD, and might serve as a marker of AD progression and treatment response. We aim to evaluate a TSPO-specific radioligand [18 F]PBR06 for visualizing alterations in TSPO and microglial activation in a transgenic mouse model of AD, Thy1-hAPP Lond/Swe (APP L/S). APP L/S mice (n=5) and wild-type (wt) littermates (n=5) underwent [18 F]PBR06-PET/computed tomography (CT) imaging at either 9–10 months or 15–16 months of age. 7T magnetic resonance (MR) images were fused with PET/CT data (attenuation corrected) to quantify [18 F]PBR06 uptake in hippocampus (H) and cortex (Ctx). Brain sections from mice were analyzed via digital autoradiography (ARG), and subsequently stained to evaluate levels of microglia (CD68), plaques (ThioS), and TSPO. Brain [18 F]PBR06 signal was significantly higher in 15–16 month APP L/S mice compared to wts (1.36 ± 0.06 vs. 1.06 ± 0.10 %ID/g, p<0.05); however, no significant difference was found between 9–10 month old mice (p = 0.49). Analysis of specific brain regions known to contain increasing levels of microglial activation in AD revealed an even greater difference in [18 F]PBR06 signal (normalized to muscle) between 15–16 month old APP L/S and wts (Ctx: 1.52 ± 0.09 vs. 0.87 ± 0.14, p<0.005; H: 1.59 ± 0.13 vs. 0.92 ± 0.14, p<0.005). Similarly, ARG images showed significantly higher [18 F]PBR06 signal in 15–16 month APP L/S mice compared to wts (Ctx: 1.32 ± 0.04 vs. 1.00 ± 0.10 %ID/g, p<0.005; H: 1.36 ± 0.06 vs. 1.07 ± 0.01 %ID/g, p<0.05). Unexpectedly, we observed a significantly higher signal in the choroid plexus of APP L/S mice in ARG images (1.99 ± 0.05 vs. 1.53 ± 0.02, p<0.005). This is the first demonstration of TSPO-related molecular alterations in the choroid plexus of an AD mouse model. Lastly, we showed that ARG and PET results correlated well with immunostaining - i.e., increased [18 F]PBR06 uptake in brain regions containing elevated CD68, ThioS, and TSPO staining in APP L/S compared to wts. [18 F]PBR06 -PET/MR imaging shows great potential as a tool for investigating the in vivo role of microglia and TSPO in the progression and treatment of AD. Results from [18F]PBR06-PET/MRI mouse brain imaging and ex vivo autoradiography (ARG). A) Coronal PET/CT/MRI images of [18F]PBR06 accumulation in APPL/S versus wild-type (wt) mice at 15–16 months of age; B) Ex vivo ARG of coronal APPL/S and wt mouse brain sections shown on the same scale. Nissl staining of same sections are shown below for anatomical correlation. Ctx = cortex and H = hippocampus. Arrows point to choroid plexus.

Imaging Glucose Metabolism and Dopaminergic Dysfunction in Sheep (Ovis aries) Brain Using Positron Emission Tomography Imaging Reveals Abnormalities in OVT73 Huntington's Disease Sheep

Metabolic disruption identified in the Huntington’s disease transgenic sheep model

A Multi-Omic Huntington's Disease Transgenic Sheep-Model Database for Investigating Disease Pathogenesis

Exploratory Dual PET imaging of [18F] fluorodeoxyglucose and [11C]acetoacetate in type 2 diabetic nonhuman primates

[A study of microPET for assessing regional cerebral glucose metabolism and the expression of dopamine receptor type 2 in a rat model of Parkinson's disease].

In vivo Imaging With 18F-FDG- and 18F-Florbetaben-PET/MRI Detects Pathological Changes in the Brain of the Commonly Used 5XFAD Mouse Model of Alzheimer's Disease

Imaging Mutant Huntingtin Aggregates using [18F]CHDI-650 PET in a preclinical model of Huntington’s disease

Development of a model for Parkinson's disease in sheep using unilateral intracarotid injection of MPTP via slow continuous infusion

The Translational Benefits of Sheep as Large Animal Models of Human Neurological Disorders

Assessment of the In Vivo Relationship Between Cerebral Hypometabolism, Tau Deposition, TSPO Expression, and Synaptic Density in a Tauopathy Mouse Model: a Multi-tracer PET Study

Brain urea increase is an early Huntington’s disease pathogenic event observed in a prodromal transgenic sheep model and HD cases

Longitudinal preclinical evaluation of the novel radioligand [11C]CHDI-626 for PET imaging of mutant huntingtin aggregates in Huntington’s disease

O2–11–05: Imaging Microglial Activation in a Mouse Model of Alzheimer's Disease Using PET/MRI and Ex Vivo Autoradiography

P1‐408: 18F‐FDG AND 18F‐AV45 POSITRON EMISSION TOMOGRAPHY IN ALZHEIMER'S DISEASE

Volumetric MRI-Based Biomarkers in Huntington's Disease: An Evidentiary Review

Connections between the internal and the external capsules and the globus pallidus in the sheep: A dichromate stain X‐ray microtomographic study

Sheep (Ovis aries) training protocol for voluntary awake and unrestrained structural brain MRI acquisitions

Preclinical evaluation of the novel [18F]CHDI-650 PET ligand for non-invasive quantification of mutant huntingtin aggregates in Huntington's disease

Abnormally abrupt transitions from sleep-to-wake in Huntington’s disease sheep (Ovis aries) are revealed by automated analysis of sleep/wake transition dynamics

In Vivo [18F]SMBT‐1 Imaging of Reactive Astrocytes in Mouse Models of Alzheimer’s Disease ‐ Temporospatial Relationship with Amyloid, Tau and Microgliosis

Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy